<DOC>
	<DOCNO>NCT02635243</DOCNO>
	<brief_summary>Primary Objective : To assess pharmacodynamic response ( PD ) single subcutaneous ( SC ) dose SAR438544 versus recombinant glucagon type 1 diabetes mellitus ( T1DM ) patient induced hypoglycemia . Secondary Objective : To assess safety tolerability pharmacokinetics ( PK ) single SC dose SAR438544 versus recombinant glucagon T1DM patient induce hypoglycemia .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics Single Dose SAR438544 Comparison Glucagon Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia</brief_title>
	<detailed_description>The total duration study per patient 8 week 3 28 day screen period , 1 day treatment period 7 14 day wash 2 administration , 7 day ( +/- 1 day ) follow-up last IMP administration .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Male female patient , 18 60 year age , inclusive , T1DM least one year , define American Diabetes Association ( ADA ) . Total ( basal+short act ) daily insulin dose &lt; 1.2 U/kg/day . Body weight 50.0 110 kg , inclusive , body mass index ( BMI ) 18.5 30.0 kg/m^2 , inclusive . Fasting serum Cpeptide &lt; 0.3 nmol/L . Glycohemoglobin ( HbA1c ) ≤75 mmol/mol ( ≤9 % ) . Stable insulin regimen least 2 month prior study selfmonitoring blood glucose screen visit . Certified otherwise healthy T1DM assessment medical history physical examination ( cardiovascular system , chest lung , thyroid , abdomen , nervous system , skin mucosa , musculoskeletal system ) , unless Investigator considers abnormality clinically irrelevant interfere conduct study . Female subject must use double contraception method , include highly effective method birth control , except undergone sterilization define tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy , bilateral tubal ligation least 3 month earlier postmenopausal . The accepted double contraception method include use intrauterine device hormonal contraception start least 30 day prior screen start continue least 3 month IMP dose addition one follow contraceptive option : ( 1 ) condom plus spermicide ; ( 2 ) diaphragm plus spermicide cervical/vault cap plus spermicide . Menopause define amenorrheic least 2 year plasma folliclestimulating hormone ( FSH ) level &gt; 30 UI/L woman older 40 year age . Having give write informed consent prior undertake studyrelated procedure . Not administrative legal supervision . Male subject , whose partner childbearing potential ( include lactate woman ) , must accept use , sexual intercourse , double contraception method accord follow algorithm : ( condom , diaphragm cervical cap , plus spermicide ) plus ( intrauterine device hormonal contraceptive ) inclusion 3 month last dosing ( except sterilize ) . Male subject whose partner pregnant must use sexual intercourse condom inclusion 3 month last dosing . Male subject agree donate sperm inclusion 3 month last dosing . Exclusion criterion : Any history presence clinically relevant cardiovascular ( include ischemia , atrioventricular ( AV ) block ; arrhythmia ) , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart T1DM ) , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . Severe hypoglycemia result coma/seizures require assistance another person , and/or hospitalization diabetic ketoacidosis last 6 month screen visit . Frequent severe headache and/or migraine , recurrent nausea and/or vomit ( twice month ) . Blood loss ( &gt; 300 mL ) within 3 month inclusion . Symptomatic postural hypotension , irrespective decrease blood pressure ( BP ) , asymptomatic postural hypotension define decrease systolic BP ≥20 mmHg within 3 minute change supine stand position . Presence history drug hypersensitivity , allergic disease diagnose treated physician . Likelihood require treatment study period drug permit clinical study protocol . If female , pregnancy ( define positive betahuman chorionic gonadotropin [ βHCG ] blood test ) , breastfeed screen treatment period ( define positive βHCG urine test ) . Any patient , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development . Positive result follow test : hepatitis B surface antigen ( HBs Ag ) , antihepatitis C virus ( HCV ) Abs , antihuman immunodeficiency virus 1 ( HIV1 ) antiHIV2 Abs , HIV1 Ag . Positive result urine drug screen ( amphetamines/methamphetamines , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . Positive alcohol breath test . Known hypersensitivity glucagon , lactose constituent GlucaGen^® HypoKit SAR438544 Novolin^®R excipients . Any contraindication use glucagon : Pheochromocytoma Insulinoma glucagonoma The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>